Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 1356 |
| PDBID: | 5FV2 |
| Chains: | B_V |
| Organism: | Homo sapiens |
| Method: | XRD |
| Resolution (Å): | 3.45 |
| Reference: | 10.1074/jbc.M115.691162 |
| Antibody | |
| Antibody: | 5FV2 VH-sdAb |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | Human Vascular Endothelial Growth Factor |
| Antigen mutation: | No |
| Durg Target: | P15692 |
Sequence information
Antibody
Chain: B
Mutation: NULL
| >5FV2_B|Chain A, B, C|VH DOMAIN ANTIBODY|HOMO SAPIENS (9606) EVQLLVSGGGLVQPGGSLRLSCAASGFTFKAYPMMWVRQAPGKGLEWVSEISPSGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPRKLDYWGQGTLVTVSS |
Antigen
Chain: V
Mutation: NULL
| >5FV2_V|Chain D[auth V], E[auth W], F[auth X]|VASCULAR ENDOTHELIAL GROWTH FACTOR|HOMO SAPIENS (9606) APMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDRHHHHHH |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| B: PHE27 THR28 ALA31 TYR32 PRO33 MET35 VAL37 LYS43 LEU45 GLU46 TRP47 GLU50 PRO53 LYS98 ASP99 PRO100 ARG101 LYS102 LEU103 V: LYS16 PHE17 MET18 TYR21 GLN22 TYR25 CYS26 HIS27 ASN62 ASP63 LEU66 LYS101 GLU103 CYS104 ARG105 PRO106 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
